OBJECTIVES: To determine the temporal relationship between antibiotic use and incidence of antibiotic-resistant Escherichia coli in both the inpatient and outpatient setting of a large urban area. METHODS: A retrospective observational time-series analysis was performed to evaluate the incidence of non-duplicate clinical isolates of E. coli resistant to ciprofloxacin, trimethoprim/sulfamethoxazole and cefepime from January 2000 through December 2007, combined with a transfer function model of aggregated data on antibiotic use in both settings obtained from the hospital's pharmacy and outpatient billing offices. RESULTS: Ciprofloxacin resistance increased from 6.0% (2000) to 15.4% (2007; P<0.0001) and cefepime resistance from 0.9% (2002) to 3.2% (2007; P=0.01). Trimethoprim/sulfamethoxazole resistance remained stable (23.7%-25.8%). Total antibiotic use increased in both settings, while fluoroquinolone use increased significantly only among outpatients. A temporal effect between fluoroquinolone resistance in community E. coli isolates and outpatient use of ciprofloxacin (immediate effect and time lag 1 month) and moxifloxacin (time lag 4 months) was observed, explaining 51% of the variance over time. The incidence of cefepime resistance in E. coli was correlated with ciprofloxacin use in the inpatient (lag 1 month) and outpatient (lag 4 months) settings and with the use of ceftriaxone (lag 0 month), piperacillin/tazobactam (3 months) and cefepime (3 months) in the hospital (R2=51%). CONCLUSIONS: These results support efforts to reduce prescribing of fluoroquinolones for control of resistant E. coli including extended-spectrum β-lactamase producers and show the added value of time-series analysis to better understand the interaction between community and hospital antibiotic prescribing and its spill-over effect on antibiotic resistance.
OBJECTIVES: To determine the temporal relationship between antibiotic use and incidence of antibiotic-resistant Escherichia coli in both the inpatient and outpatient setting of a large urban area. METHODS: A retrospective observational time-series analysis was performed to evaluate the incidence of non-duplicate clinical isolates of E. coli resistant to ciprofloxacin, trimethoprim/sulfamethoxazole and cefepime from January 2000 through December 2007, combined with a transfer function model of aggregated data on antibiotic use in both settings obtained from the hospital's pharmacy and outpatient billing offices. RESULTS:Ciprofloxacin resistance increased from 6.0% (2000) to 15.4% (2007; P<0.0001) and cefepime resistance from 0.9% (2002) to 3.2% (2007; P=0.01). Trimethoprim/sulfamethoxazole resistance remained stable (23.7%-25.8%). Total antibiotic use increased in both settings, while fluoroquinolone use increased significantly only among outpatients. A temporal effect between fluoroquinolone resistance in community E. coli isolates and outpatient use of ciprofloxacin (immediate effect and time lag 1 month) and moxifloxacin (time lag 4 months) was observed, explaining 51% of the variance over time. The incidence of cefepime resistance in E. coli was correlated with ciprofloxacin use in the inpatient (lag 1 month) and outpatient (lag 4 months) settings and with the use of ceftriaxone (lag 0 month), piperacillin/tazobactam (3 months) and cefepime (3 months) in the hospital (R2=51%). CONCLUSIONS: These results support efforts to reduce prescribing of fluoroquinolones for control of resistant E. coli including extended-spectrum β-lactamase producers and show the added value of time-series analysis to better understand the interaction between community and hospital antibiotic prescribing and its spill-over effect on antibiotic resistance.
Authors: Munther S Alnajjar; Mamoon A Aldeyab; Michael G Scott; Mary P Kearney; Glenda Fleming; Fiona Glimore; David Farren; James C McElnay Journal: Infection Date: 2019-05-07 Impact factor: 3.553
Authors: Shiona K Glass-Kaastra; Rita Finley; Jim Hutchinson; David M Patrick; Karl Weiss; John Conly Journal: Can J Infect Dis Med Microbiol Date: 2014-03 Impact factor: 2.471
Authors: N Goffinet; N Lecadet; M Cousin; C Peron; J-B Hardouin; E Batard; E Montassier Journal: Eur J Clin Microbiol Infect Dis Date: 2014-01-18 Impact factor: 3.267
Authors: O Grignon; E Montassier; S Corvec; D Lepelletier; J-B Hardouin; J Caillon; E Batard Journal: Eur J Clin Microbiol Infect Dis Date: 2014-10-23 Impact factor: 3.267
Authors: Mamoon A Aldeyab; Stephan Harbarth; Nathalie Vernaz; Mary P Kearney; Michael G Scott; Feras W Darwish Elhajji; Motasem A Aldiab; James C McElnay Journal: Br J Clin Pharmacol Date: 2012-07 Impact factor: 4.335
Authors: Jameson B Wood; Donald B Smith; Errol H Baker; Stephen M Brecher; Kalpana Gupta Journal: Antimicrob Agents Chemother Date: 2012-08-20 Impact factor: 5.191